Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v9-EN | Version v3-EN | |
|---|---|---|
| Language | English | English |
| Date Updated | 2025-02-06 | 2025-01-27 |
| Drug Identification Number | 02487454 | 02487454 |
| Brand name | SKYRIZI | SKYRIZI |
| Common or Proper name | Risankizumab | Risankizumab |
| Company Name | ABBVIE CORPORATION | ABBVIE CORPORATION |
| Ingredients | RISANKIZUMAB | RISANKIZUMAB |
| Strength(s) | 75MG | 75MG |
| Dosage form(s) | SOLUTION | SOLUTION |
| Route of administration | SUBCUTANEOUS SUBCUTANEOUS | SUBCUTANEOUS SUBCUTANEOUS |
| Packaging sizes (GTIN) | (See additional packaging sizes) | (See additional packaging sizes) |
| Additional packaging sizes | 2 x 75mg/0.83 mL Syringe | 2 x 75mg/0.83 mL Syringe |
| ATC code | L04AC | L04AC |
| ATC description | ||
| Reason for discontinuation | Other (Please describe in comments) | Other (Please describe in comments) |
| Anticipated discontinuation date | 2024-12-16 | 2024-12-16 |
| Actual discontinuation date | 2024-12-16 | 2024-12-16 |
| Remaining supply date | 2023-09-01 | 2023-07-31 |
| Discontinuation status | Discontinued | Discontinued |
| Discontinuation decision reversal | no | no |
| Tier 3 Status | No | No |
| Information on remaining supply | ||
| Company comments | The shortage was posted in 2023. No replenishment was received since then. Refer to the shortage posting for details. The company decision to discontinue was made at the end of 2024. | The shortage was posted in 2023. The decision for discontinuation was made at the end of 2024. |
| Health Canada comments |